MCA logo
MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

Press Release: CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

cytomed
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: